Indivior Pharmaceuticals, Inc.— Sankey Diagram
Quarterly mode · period ending 2026-03-31 · SEC EDGAR
ComparingFY2026 (Q4) vs FY2025 (Q4)
Revenue
$317M
↑+19.2% +$51Mvs FY2025 (Q4)
Gross Profit
$277M
↑+24.9% +$55Mvs FY2025 (Q4)
Operating Income
$137M
↑+107.6% +$71Mvs FY2025 (Q4)
Net Income
$89M
↑+89.4% +$42Mvs FY2025 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2026 (Q4) | FY2025 (Q4) |
|---|---|---|
| Revenue | $317M | $266M |
| COGS | $40M | $44M |
| Gross Profit | $277M | $222M |
| R&D | $16M | $22M |
| SG&A | $124M | $133M |
| D&A | $0 | $834K |
| Other OpEx | $0 | $0 |
| Operating Income | $137M | $66M |
| Interest Exp. | $7M | $7M |
| Other Non-Op | $15M | $0 |
| Pretax Income | $115M | $59M |
| Tax | $26M | $12M |
| Net Income | $89M | $47M |
QuarterCharts · SEC EDGAR data · INDV · Comparing FY2026 (Q4) vs FY2025 (Q4)